Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Arbovirus-Associated Guillain-Barré Syndrome: A Systematic Review and Meta-Analysis of Clinical Characteristics, Subtypes, and Vaccine Associations.

Immunity, inflammation and disease·2026
Same author

Timely Response: Enhancing Africa's Ebola Outbreak Management through Unified Evidence.

QJM : monthly journal of the Association of Physicians·2026
Same author

Can stochastic modelling predict cross-border spread of the Bundibugyo Ebola virus outbreak in Africa?

The Lancet. Infectious diseases·2026
Same author

Capacity building for genomic surveillance of mpox and other emerging diseases in resource-limited settings within the African Great Lakes region.

Communications medicine·2026
Same author

Imported cases of dengue in Rwanda: A call for One Health integrated surveillance and response system for arboviral diseases.

IJID regions·2026
Same author

Survival and risk factors of mortality among patients with TB/HIV coinfection in Kigali City, Rwanda: a retrospective cohort study (2019-2024).

BMC infectious diseases·2026

Related Experiment Video

Updated: Jul 2, 2026

Remote Laboratory Management: Respiratory Virus Diagnostics
14:56

Remote Laboratory Management: Respiratory Virus Diagnostics

Published on: April 6, 2019

Rwanda's National Reference Laboratory Operational Capacity during the 2024 Marburg Virus Disease Outbreak Response.

Noel Gahamanyi1, Naasson Tuyiringire2, Jerome Ndayisenga3

  • 1Rwanda Biomedical Centre, KG 644 St, Kigali, P.O. Box 7162, Kigali, Kimihurura, Rwanda. noel.gahamanyi@rbc.gov.rw.

Tropical Diseases, Travel Medicine and Vaccines
|July 1, 2026
PubMed
Summary

Rwanda's National Reference Laboratory demonstrated strong operational capacity during the 2024 Marburg Virus Disease outbreak, achieving a 98% score. Key improvements included reduced turnaround times and expanded testing sites, though External Quality Assessment for MVD is recommended.

Keywords:
Marburg virus diseaseNational Reference LaboratoryOutbreakQuality management systemResponseRwanda

More Related Videos

Field Postmortem Rabies Rapid Immunochromatographic Diagnostic Test for Resource-Limited Settings with Further Molecular Applications
07:40

Field Postmortem Rabies Rapid Immunochromatographic Diagnostic Test for Resource-Limited Settings with Further Molecular Applications

Published on: June 29, 2020

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency
09:04

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

Published on: May 11, 2020

Related Experiment Videos

Last Updated: Jul 2, 2026

Remote Laboratory Management: Respiratory Virus Diagnostics
14:56

Remote Laboratory Management: Respiratory Virus Diagnostics

Published on: April 6, 2019

Field Postmortem Rabies Rapid Immunochromatographic Diagnostic Test for Resource-Limited Settings with Further Molecular Applications
07:40

Field Postmortem Rabies Rapid Immunochromatographic Diagnostic Test for Resource-Limited Settings with Further Molecular Applications

Published on: June 29, 2020

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency
09:04

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

Published on: May 11, 2020

Area of Science:

  • Public Health
  • Infectious Disease Epidemiology
  • Laboratory Science

Background:

  • Rwanda experienced its first Marburg Virus Disease (MVD) outbreak in September 2024.
  • This study assesses the operational capacity of Rwanda's National Reference Laboratory (NRL) during the MVD outbreak response.

Purpose of the Study:

  • To evaluate the National Reference Laboratory's operational capacity during the 2024 Marburg Virus Disease outbreak.
  • To identify strengths and areas for improvement in the laboratory response to viral hemorrhagic fevers.

Main Methods:

  • Utilized the World Health Organization laboratory assessment tool for viral hemorrhagic fever (VHF) diagnostic capacity.
  • Assessed laboratory quality indicators, including turnaround time (TAT).
  • Collected data through direct observation, document review, and staff interviews; analyzed using Microsoft Excel and QGIS software.

Main Results:

  • The NRL achieved an overall operational capacity score of 98%.
  • Significant achievements include reducing TAT from 24 to 7 hours, expanding testing sites, and enhancing staff training.
  • The laboratory system scored 89% in quality due to the absence of External Quality Assessment (EQA) for MVD.

Conclusions:

  • Rwanda's NRL demonstrated a robust system for effective MVD case testing.
  • Recommendations include implementing an EQA scheme for VHF diagnostics and enhancing biosafety measures across health facilities.